Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828336 | 1.00 | IDUA (0.31) | IDUA | |
| SCHEMBL16629463 | 1.00 | IDUA (0.31) | IDUA | |
| SCHEMBL18016490 | 0.79 | — | — | |
| SCHEMBL12959176 | 0.79 | — | — | |
| SCHEMBL15828225 | 0.79 | — | — | |
| SCHEMBL21067531 | 0.78 | IDUA (0.47) | IDUA | |
| SCHEMBL21067530 | 0.78 | IDUA (0.47) | IDUA | |
| SCHEMBL4392530 | 0.78 | IDUA (0.47) | IDUA | |
| SCHEMBL3975872 | 0.77 | — | — | |
| SCHEMBL3982678 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10266825-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-7307069-B2 | Antisense oligonucleotide modulation of STAT3 expression | ISIS PHARMACEUTICALS, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7235653-B2 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070135364-A1 | Compositions and methods for the modulation of the expression of b7 protein | ISIS PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070054869-A1 | Antisense modulation of superoxide dismutase 1, soluble expression | BIOGEN MA INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054869-A1 | Antisense modulation of superoxide dismutase 1, soluble expression | BIOGEN MA INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070015722-A1 | Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation | BANK OF AMERICA, N.A. | 2007-01-18 | — | — | US | disclosed |
| US-20070015722-A1 | Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation | BANK OF AMERICA, N.A. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | IDUA 1953/4885 |
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | IDUA 2805/4885 |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | IDUA 2805/4885 |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | CD2BP2, MICA, CD74 | IDUA 4793/4885 |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | NSUN2, SNRPE, RBM3 | IDUA 2718/4885 |
| US-20070135364-A1 | Compositions and methods for the modulation of the expression of b7 protein | CD2BP2, CD74, CD47 | IDUA 4410/4885 |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | NSUN2, RNMT, NSUN3 | IDUA 1960/4885 |
| US-20070054869-A1 | Antisense modulation of superoxide dismutase 1, soluble expression | SOD1, SOD3, RNASE1 | IDUA 198/4885 |
| US-10266825-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | IDUA 1953/4885 |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | RPP30, NOP10, NR0B1 | IDUA 4213/4885 |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | IDUA 2805/4885 |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | IDUA 2805/4885 |
| US-20070015722-A1 | Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation | NSUN2, NSUN3, RNMT | IDUA 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.